Synaptogenix, Inc. financial data

Symbol
SNPX on Nasdaq
Industry
Pharmaceutical Preparations
Location
1185 Avenue Of The Americas, 3 Rd Floor, New York, NY
State of incorporation
DE
Fiscal year end
December 31
Former names
NEUROTROPE BIOSCIENCE, INC. (to 11/20/2020)
Latest financial report
10-Q - Q2 2024 - Aug 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 550 % -75.5%
Debt-to-equity 27.8 %
Return On Equity -7.45 % +50.5%
Return On Assets -5.65 % +55.9%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 1.31M shares -87.1%
Common Stock, Shares, Outstanding 1.25M shares -83%
Entity Public Float 6.62M USD -81.2%
Common Stock, Value, Issued 127 USD -82.8%
Weighted Average Number of Shares Outstanding, Basic 1.21M shares +310%
Weighted Average Number of Shares Outstanding, Diluted 1.21M shares +310%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 1.74M USD -57.3%
General and Administrative Expense 5.09M USD -47.6%
Nonoperating Income (Expense) 5.12M USD -45.8%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -1.71M USD +60.6%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -1.71M USD +60.6%
Earnings Per Share, Basic -28.5 USD/shares -208%
Earnings Per Share, Diluted 5 USD/shares +93.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 25M USD -24.1%
Assets, Current 27.8M USD -16.7%
Property, Plant and Equipment, Net 15.8K USD -26.4%
Assets 28.4M USD -15.1%
Accounts Payable, Current 475K USD +8.24%
Accrued Liabilities, Current 47.5K USD -30.3%
Liabilities, Current 9.35M USD +237%
Liabilities 9.59M USD +46.8%
Accumulated Other Comprehensive Income (Loss), Net of Tax 302 USD
Retained Earnings (Accumulated Deficit) -35.5M USD -10.8%
Stockholders' Equity Attributable to Parent 18.8M USD -24.3%
Liabilities and Equity 28.4M USD -15.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.83M USD -8%
Net Cash Provided by (Used in) Financing Activities 553K USD -95.6%
Net Cash Provided by (Used in) Investing Activities -500K USD -24434%
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 1.25M shares -83%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 25M USD -24.1%
Deferred Tax Assets, Valuation Allowance 30.2M USD +14.8%
Payments to Acquire Property, Plant, and Equipment 2.04K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -1.43M USD +86%
Deferred Tax Assets, Operating Loss Carryforwards 30.9M USD +12.8%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 1M shares 0%
Additional Paid in Capital 54.3M USD -4.55%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 1.4K USD -17.2%
Share-based Payment Arrangement, Expense 48K USD -98.2%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%